Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 677 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR ΠΟΝΟΣ March 8, 2019 EMA Recommends Granting a Marketing Authorisation for Fedratinib December 23, 2020 Feeling the pull: Using magnetic drug targeting to improve chemotherapy in... February 16, 2023 FDA Approves Nivolumab in Combination with Chemotherapy and Nivolumab in Combination... June 8, 2022 Load more HOT NEWS Expecting Mom Finds Pregnant Stray Cat And Gives Her A Home Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with... Qué debe saber sobre las pruebas de ADN en el hogar... Biopsia por aspiración con aguja fina (PAAF): Cómo prepararse y qué...
